GlassScriptPhysician profile
Donald Kulbeth
NPI 1982870788
$11,936.01
in general payments reported to CMS, 2019-2025
53 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,480 · 2022: $2,574 · 2023: $2,621 · 2024: $2,186 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,881.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.48 | 2021-2025 | |
| Novo Nordisk INC | $1,160.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $920.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $781.84 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $778.72 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $725.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $612.21 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $611.38 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.78 | 2021-2025 | Jardiance, Ofev |
| Corium, LLC | $348.40 | 2022-2024 | Azstarys |
| Amgen INC. | $338.09 | 2021-2025 | Repatha, Repatha, Evenity |
| Astellas Pharma US INC | $334.39 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $331.87 | 2021-2025 | |
| Amarin Pharma, INC. | $303.87 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $258.22 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Kulbeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.